Kyverna Appoints Mayo Pujols as Chief Technology Officer, Successor to Karen Walker.

Kyverna Therapeutics has appointed Mayo Pujols as its Chief Technology Officer, effective February 9, 2026. Pujols brings over 30 years of experience in leading late-stage and commercial manufacturing for cell and gene therapies. He succeeds Karen Walker, who is retiring, and will oversee the transition to a commercial-stage company as Kyverna prepares for the potential launch of miv-cel in stiff person syndrome. Pujols has a proven track record of disciplined execution and operational delivery, having held various roles at companies such as Castle Creek Biosciences, Rocket Pharmaceuticals, and Novartis.